TABLE 1.
Information of study groups and participants.
| Groups | HIV- LTBI+ (n = 22) | HIV-PTB+ (n = 21) |
HIV-EPTB+ (n = 33) | HIV+PTB+ (n = 14) | HIV+LTBI + (n = 17) | HIV+ LTBI- (n = 41) | |
| Non-severe (n = 10) | Severe (n = 11) | ||||||
| Age (years): Median (range) | 35 (19–45) | 27.5 (17–65) | 28 (18–63) | 30 (16–60) | 39 (22–60) | 36 (24–56) | 37 (27–53) |
| Sex (M:F) | 16:6 | 9: | 7:4 | 22:11 | 10: 4 | 5:12 | 15:26 |
| CD4 (cells/mm3): Median (range) | Not done | Not done | Not done | Not done | 150 (80–525) | 308 (148–1565) | 335 (19–1207) |
| CD4%:Median (range) | Not done | Not done | Not done | Not done | 12 (8–22) | 17 (7–46) | 22 (2–49) |
| Viral load (copies/ml): Median (range) | Not done | Not done | Not done | Not done | 251540 (1155–434510) | 458227 (46816–1606720) | 14340 (115–4963079) |
| IGRA positivity | 22 (100%) | Not done | Not done | Not done | Not done | 17 (100%) | 0 (0%) |
| Organs involved | Not applicable | Lungs | Lungs | Pleural effusion (23), abdominal (4), spine (1), miliary (2), cold abscess (3) | Lungs | Not applicable | Not applicable |